【导读】赛微电子完成瑞典Silex控股权的出售交割 中国基金报记者 杨晨 7月25日晚间，赛微电子（证券代码：300456）发布公告称，公司已完成向Bure Equity AB、Creades AB（publ）等七名交易对方转让全资子公司Silex Microsystems AB（以下简称瑞典Silex）控制权的重大资产出售交割事项。 公告称，本次交易构成《上市公司重大资产重组管理办法》规定的重大资产重组，不构成关联交易。目前，交易各方已根据《股份买卖协议》的约定完 成交割，交易对方已经成为标的公司股东。 控制权卖了近18亿元 仍保留瑞典Silex 45.24%的股份 本次交易的出售方系赛微电子的全资子公司运通电子。本次交易前，瑞典Silex为赛微电子的全资子公司，赛微电子通过运通电子持有瑞典Silex87.80% 的股份，并通过全资子公司赛莱克斯国际持有瑞典Silex12.20%的股份。 本次交易完成后，赛微电子通过全资子公司合计持有瑞典Silex 45.24%的股份，瑞典Silex将成为赛微电子的参股公司。 本次交易的标的资产为运通电子持有的瑞典Silex 的441万股股份。 经各方协商，瑞典Silex初 ...

【导读】赛微电子完成瑞典 Silex 控股权的出售交割 中国基金报记者 杨晨 7 月 25 日晚间，赛微电子（证券代码： 300456 ）发布公告称，公司已完成向 Bure Equity AB 、 Creades AB （ publ ）等七名交易对方转让全资子公司 Silex Microsystems AB （以下简称瑞典 Silex ）控制权的重大资产出售交割事项。 公告称，本次交易构成《上市公司重大资产重组管理办法》规定的重大资产重组，不构成关 联交易。目前，交易各方已根据《股份买卖协议》的约定完成交割，交易对方已经成为标的 公司股东。 控制权卖了近 18 亿元 仍保留瑞典 Silex 45.24% 的股份 本次交易的出售方系赛微电子的全资子公司运通电子。本次交易前，瑞典 Silex 为赛微电子 的全资子公司，赛微电子通过运通电子持有瑞典 Silex87.80% 的股份，并通过全资子公司赛 莱克斯国际持有瑞典 Silex12.20% 的股份。 本次交易完成后，赛微电子通过全资子公司合计持有瑞典 Silex 45.24% 的股份，瑞典 Silex 将成为赛微电子的参股公司。 本次交易的标的资产为运通电子持有 ...

作者 | 闰然 统筹 | 张鹏霞 视觉 | 顾芗 现在许多年轻人，对着镜子发现第一道细纹的慌张程度，堪比下班前突然接到老板的紧急电话。 初老焦虑，某种程度上是被社交媒体放大的集体恐慌，让很多人带着"再不动手就晚了"的紧迫感冲进医 美机构，结果慌不择路踩了坑：打了来源不明的针剂，被推销了根本不需要的项目。 很多人在这个过程中变成了待割的韭菜，还是自己主动递刀的那种。可医美不是买衣服，脸搞砸了没有 后悔药。面对医美机构，以前是"你敢吹，我敢信"，而现在必须是"你敢验，我才认"。 在脸上赌运气？ 小区美容院的阿姨拉着你往黑机构拐，说给你打个折就能换张脸。你进去的时候，只是想打个瘦脸针， 但出来的时候可能被忽悠着做了"干细胞填充"，账单金额能让你怀疑自己是不是不小心签了个器官捐献 协议。 更绝的是那些"伪科普"套路。"医美达人"对着镜头说，"我这鼻子三万块做的，效果绝了"，转头就拿着 机构给的五万块返佣去买包。她们给你推荐的"神仙项目"，可能是连国家药监局都查不到备案的野路 子。 验真路上也是"九九八十一难"。你在网上认认真真做好功课，知道医美仪器是可以验真的。可每个仪器 品牌都像藏着独家秘籍，验证路径也是五花八门， ...

Core Viewpoint - EFL is focused on the development and application of bioprinting technologies, particularly in regenerative medicine, showcasing its innovations at the upcoming 2025 Polymer 3D Printing Materials Summit [1][21]. Company Overview - EFL was established in 2017, leveraging research outcomes from Zhejiang University led by Professor He Yong [2]. - The company provides comprehensive services in regenerative medicine, encompassing scientific popularization, research services, and technology transfer [3]. Product Offerings - EFL offers several advanced products: - **Volume Photopolymerization Bioprinter**: Capable of rapid formation of cell-laden hydrogel structures with a 4K projection accuracy [4]. - **Multi-functional Extrusion Bioprinter**: Features a wide temperature control range of -25 to 260°C, suitable for various bioprinting materials [8]. - **Projection Photopolymerization Bioprinter**: Supports automatic switching of up to six inks for complex bioprinting needs [12]. - **Microneedle Manufacturing Device**: The first multifunctional desktop device for preparing hydrogel microneedles, integrating humidity and vacuum control systems [17]. - **Gelatin Methacryloyl (GelMA)**: A versatile hydrogel with excellent biocompatibility and mechanical properties, suitable for 3D cell culture and tissue engineering [19]. Technical Highlights - The bioprinters boast high printing speeds, with structures forming in seconds, and maintain a cell viability rate exceeding 95% [5][9][13]. - The devices are designed for various applications, including cell culture scaffolds, organoids, and organ-on-a-chip technologies [5][9][13]. Market Position - EFL ranks among the top three in the domestic bioprinting research market, with its photopolymerization bioprinting inks holding the leading market share [6][10][14].

Core Viewpoint - The article investigates the manipulation of online reviews and ratings by "water army" organizations, revealing a systematic approach to creating fake positive reviews and suppressing negative feedback across various e-commerce and social media platforms [1][3][4]. Group 1: Online Review Manipulation - Consumers have reported that negative reviews on certain products mysteriously disappear, while positive reviews dominate the comment sections on live-streaming e-commerce platforms [1]. - The use of coded language such as "S蛋" and "鱼塘" allows users to find hidden content related to review manipulation, despite warnings from platforms [3][4]. - A water army intermediary disclosed that positive reviews can be purchased for 1 yuan per comment, indicating a clear pricing structure for manipulating online perceptions [4][5]. Group 2: Fake Transactions and Reviews - The strategy employed by water armies involves recruiting ordinary consumers to pose as legitimate buyers, posting misleading positive reviews without having used the products [5][6]. - A specific case involved a transaction where a user was instructed to pay a significantly reduced price for a product, only to receive a refund that included a commission, illustrating the deceptive practices used to create the illusion of genuine sales [6][8]. - The article highlights that these operations are designed to evade e-commerce platform algorithms, creating a façade of authentic user engagement [6][8]. Group 3: Broader Implications and Business Models - The manipulation of reviews is not limited to individual sellers; some legitimate platforms are also implicated in promoting review manipulation for increased traffic and profits [9]. - The "freedom to explore" model on platforms like Dazhong Dianping allows users to submit reviews without actual experiences, further blurring the lines of authenticity in consumer feedback [9][11]. - The article also discusses the emergence of a "reporting business" where water armies exploit platform governance rules to extort money from users by threatening account suspensions [21][23].

导语：许多前来就诊的客户是华为员工或周边企业白领。"从公司出来顺路体验，价格确实 贵，但效果比小区美容院强多了。 2025年6月24日，深圳华为坂田基地附近的一家医美诊所悄然开业。诊所名叫"深圳大为诊所"，主 营黄金微针、冰点脱毛、水光注射等项目，大众点评显示人均消费2218元。 更令人关注的是，这家诊所的法定代表人和唯一股东，是百度前副总裁璩静——一位曾在2024年因 短视频争议引发全网热议的"职场话题人物"。 而这次选址华为总部旁的诊所，或许是她试图重新定义自己的开始。 以下文章来源于科技消费那些事 ，作者米川2024 科技消费那些事 . 关注科技消费行业的小八卦、大新闻~ 作者 | 米川 来源 | 科技消费那些事 值得注意的是，诊所的运营模式也透露出她的谨慎。尽管她是法定代表人，但工作人员表示"老板 在北京，团队未直接接触"。这种"幕后操盘"的姿态，既规避了公众关注，也留出了更多试错空间。 光环与争议并存的职业轨迹 医美诊所：高端定位与精准选址 深圳大为诊所的成立时间是2024年12月23日，但公众号显示直到2025年6月24日才正式对外营业。 尽管成立时间早，但它的开业并未引发太大波澜，直到大众点评上 ...

Summary of the Conference Call for Xinyang Company Overview - Xinyang operates in the medical aesthetics industry, primarily through an online platform that charges information service fees and commissions to medical beauty institutions. The company was founded in 2013 and went public on NASDAQ in 2019. [3][2] Key Business Developments - Xinyang acquired Wuhan Qizhi Laser for 790 million RMB to expand its photonic equipment business and is also the agent for Dongbang's hyaluronic acid products from South Korea, with a quarterly shipment of 28,000 units, a 14% year-on-year increase. [2][3] - The core business, Xinyang Youth Clinics, has opened 31 locations and plans to expand to 50 by 2025, focusing on first-tier cities. [2][5] Financial Performance - Expected revenue for 2025 is between 1.5 billion to 1.6 billion RMB, with contributions from various segments: Top business (500-600 million RMB), chain business (600 million RMB), and upstream business (300 million RMB). [3][12] - The average monthly revenue for mature clinics is 4.5 to 5 million RMB, while growing clinics average around 3 million RMB. [6][7] Customer Insights - Target customers are women aged 25-45, with the highest spending power in the 30-35 age range. The repurchase rate is approximately 60-65%. [9][10] - Average customer spending is 2,000 RMB for new customers and 2,500 RMB for returning customers. [8] Marketing and Customer Acquisition - Xinyang's customer acquisition cost is significantly lower than industry averages, with costs around 700 RMB per customer compared to 2,000-3,000 RMB for competitors. [10][22] - The company utilizes a mix of referral programs, private domain conversions, and social media advertising to attract new customers. [10][11] Operational Efficiency - The cost structure includes marketing expenses (15%), consumable costs (49-50%), personnel costs (12%), and rent/utilities (10-15%). [6][20] - The company has a strong focus on light medical aesthetics, which facilitates replication and expansion. [8] Product Development and Innovation - Xinyang plans to launch proprietary products such as the "童颜针" (youthful needle) and silk protein to enhance cost-effectiveness and competitiveness. [3][13] - New products are designed to improve user experience and reduce costs, with a focus on maintaining a competitive edge in pricing and efficacy. [14][22] Store Expansion Strategy - The company plans to open 50 stores by the end of 2025, with a mix of direct and franchise operations. [17][18] - The payback period for stores is estimated at around six months for positive cash flow and one year for breakeven. [19] Competitive Landscape - Xinyang's business model is unique in the market, with few direct competitors. Similar models exist, but they differ significantly in scale and operations. [28] Conclusion - Xinyang is positioned for growth in the medical aesthetics sector, with a solid expansion plan, innovative product offerings, and a strong customer acquisition strategy. The company aims to leverage its unique business model to maintain a competitive advantage in the industry. [2][3][28]

大会开场，来自政策端与临床一线的发言，为本次会议定下了"从需求出发、向转化落地"的主基调。 北京市医药健康科技发展中心副主任 刘刚 指出，医美作为首都医药健康产业的重要特色板块，正迎来政策体系与资源供给的双重叠加。他介绍，北京近年来在"美 丽健康"领域出台了一系列政策工具，包括 三轮医药健康行动计划、"创新药械全流程优化"试点等 ，在产业空间、资金支持、人才引育、服务机制等方面逐步形成 系统生态。 为 推动医美科技深度发展，促进创新资源要素高效集聚，2025年6月12日， 首届全球医美科技大会 （Global Aesthetic Technology Conference 2025）在北京 市中关村展示中心正式召开。大会由 思宇MedTech、探美医界 联合主办， 中关村联新生物医药产业联盟协办，启迪之星、中关村科学城CGT产业孵化中心等 提 供支持，现场汇聚临床、科研、企业、投资等领域的600余位专业嘉宾。 本次大会聚焦 再生材料、医工融合、投融资机制 等核心议题，围绕" 临床牵引+科技驱动+产业转化 "的路径，展开多维交流。现场不仅发布了多项标志性成果， 也呈现出一个清晰信号：中国医美科技正迈向系统化创新 ...

陕西云谷众惠生物医药有限公司宣布完成由昕成投资、爱康创坛联合投资的种子轮融资和由陕投成长基金、中科创星、 金资基金联合投资的天使轮融资，合计融资约5000万元人民币，并同时宣布完成对上海揽微医学科技有限公司的并购重 组。本轮融资将用于中国首家空心微针医疗器械生产基地建设和三类器械证申报、细胞与外泌体中试车间建设、西北首 个自动化生物组织样本库建设和人才队伍的完善。 空心微针是一种具有中空通道的微米级针状结构，广泛应用于药物递送、疫苗注射、医美注射、生物传感等领域，其核 心优势在于无痛、微创、载药量大且可控性强。 众惠医药在针型设计和生产端深耕多年，通过微针自主设计、微纳3D打印、光固化等核心工艺打磨，开发出可量产、 全链条生产平台，实现从实验室技术到工业化生产的跨越，储备了众多量产工艺、工程设备等方面的技术和专利，打破 了国外垄断，并将在2025年9月完成国内首条自动化生产线的建设。 专注于企业办公安全领域的零信任SASE服务商 —— 杭州亿格云科技有限公司（简称：亿格云）正式宣布完成Pre-B轮 近亿元融资。本轮融资由红杉中国领投、元璟资本、启创资本老股东持续加码，由航行资本担任财务顾问。 本轮资金将主要用 ...

Core Viewpoint - The first Global Aesthetic Technology Conference 2025 was held in Beijing, showcasing innovations in the medical aesthetics industry and promoting technology transfer and cross-industry collaboration [2] Group 1: Awards Overview - The conference featured the 2025 Global Aesthetic Technology Innovation Awards, which included three categories: Technology Innovation Award, Innovation Service Award, and Innovation Transformation Award, highlighting innovations in materials, equipment, and technology transfer in China's medical aesthetics sector [2] Group 2: Technology Innovation Award Winners - Huaxi Biological was recognized for its integration of basic research and industrial transformation, particularly through its brand Runzhi, which utilizes synthetic biology technology in hyaluronic acid and extracellular matrix [4] - Langxi Ziyuan Medical Devices focused on regenerative medicine and developed a 3D biomimetic culture system that enhances the yield and bioactivity of exosomes for chronic wound repair [5] - Weimai Qingtong Medical Technology created a new monopolar RF anti-aging system, YOUMAGIC, which has received both NMPA and FDA approvals, breaking the international brand monopoly in high-end RF equipment [7] - Suzhou Baifu Laser Technology specializes in high-end medical laser equipment, achieving significant technological breakthroughs in stability and precision, with products that meet international standards [9] - Suzhou Fumai Lei Medical Technology has developed innovative high-end medical optical devices, focusing on energy stability and treatment precision, contributing to the rise of domestic optical medical equipment [11] - Guangzhou Yicheng Biological focuses on regenerative materials and has developed various medical devices with a clear product line and compliance registration paths [12] Group 3: Innovation Service Award Winners - Beijing Tonghe Litai Biotechnology specializes in preclinical research for medical devices, having completed over 900 NMPA registration reports, ensuring scientific data and compliance for innovative medical products [14] - Beijing Baoli Yongchang Medical Technology (Lihokang) has established a mature methodology for compliance transformation services in the medical aesthetics field, facilitating the rapid market entry of innovative products [16] - Hainan Susong Biotechnology has introduced Swiss SmartBone® on Demand bone regeneration materials, demonstrating effective cross-border medical technology integration and personalized medical needs [17] Group 4: Innovation Transformation Award Winners - Yao Guijin led the establishment of an ecosystem for medical aesthetics technology transfer, facilitating collaboration among medical, research, enterprise, and regulatory sectors [19] - Professor An Yang's team developed solutions for nasal reconstruction, achieving significant advancements in tissue regeneration and repair [20] - Professor Niu Xufeng addressed common issues in skin fillers by innovating a polyester microsphere/collagen composite material system, enhancing stability and integration [21] - Professor Zhang Guifeng made breakthroughs in medical collagen research, establishing a closed-loop system for industry standards and quality control [22] Conclusion - The Global Aesthetic Technology Awards highlighted the breadth and depth of innovation in the medical aesthetics sector, showcasing the emerging strength of Chinese companies and experts in the global industry landscape [23]